<DOC>
	<DOCNO>NCT02670538</DOCNO>
	<brief_summary>This study design prospectively confirm efficacy fixed-dose regimen cariprazine 1.5 mg/day 3 mg/day compare placebo treatment depressive episode patient bipolar I disorder . The safety tolerability fixed-dose regimen evaluate .</brief_summary>
	<brief_title>Study Efficacy Fixed-dose Regimen Cariprazine Compared Placebo Treatment Depressive Episode Patients With Bipolar I Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>Currently meet Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criteria bipolar I disorder without psychotic feature confirm administration Mini International Neuropsychiatric Interview ( MINI ) , current major depressive episode least 4 week exceed 12 month duration Currently treat outpatient time enrollment A verify previous manic mixed episode . Verification must include one follow source : Treatment mania antimanic agent ( eg , lithium divalproate ) antipsychotic medication approve indication mania Hospital records/Medical record Patient report corroborate caretaker previous current treat clinician 17item Hamilton Depression Rating Scale ( HAMD17 ) total score ≥ 20 HAMD17 item 1 score ≥ 2 CGIS score ≥ 4 Negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test ( woman childbearing potential ) Normal physical examination , clinical laboratory test result , electrocardiogram ( ECG ) result abnormal finding judge clinically significant Principal Investigator ( PI ) Young Mania Rating Scale ( YMRS ) total score &gt; 12 Four episode mood disturbance ( depression , mania , hypomania , mixed state ) within 12 month Visit 1 Any current axis 1 psychiatric diagnosis bipolar disorder exception specific phobias History meeting DSM5 criterion : Dementia , amnesic , cognitive disorder Schizophrenia , schizoaffective , psychotic disorder Mental retardation DSM5based diagnosis borderline antisocial personality disorder axis II disorder sufficient severity interfere participation study History meeting DSM5 criterion alcohol substance abuse dependence ( nicotine caffeine ) within 6 month Visit 1 Positive result blood alcohol test urine drug screen prohibit medication . Exception : patient positive cannabinoid entry may retested randomization . If patient remain positive , patient longer eligible patient positive opiate entry , discussion Study Physician require . Electroconvulsive therapy 3 month Visit 1 Previous lack response electroconvulsive therapy Treatment depot antipsychotic drug within 1 treatment cycle Visit 1 Treatment clozapine dose &gt; 50 mg/day past 2 year Prior participation investigational study RGH188 cariprazine within past 12 month Previous treatment vagus nerve stimulation transcranial magnetic stimulation within 6 month Visit 1 Prior participation clinical trial , involve experimental investigational drug , within 6 month Visit 1 study Initiation termination psychotherapy depression within 3 month precede Visit 1 , plan initiate , terminate , change therapy course study . Pregnant , breastfeeding , plan become pregnant breastfeed study Gastric bypass condition would expect affect drug absorption ( lap band procedure acceptable problem absorption ) Known history cataract retinal detachment Known human immunodeficiency virus infection Employee , immediate relative employee , Sponsor , affiliate partner , study center</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>